IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640837
Tyler S Oesterle, Nicholas L Bormann, Mark A Lifson, Katina Michael
{"title":"A Substance Use Disorder Virtual Treatment and Research Platform: A Proof of Concept.","authors":"Tyler S Oesterle, Nicholas L Bormann, Mark A Lifson, Katina Michael","doi":"10.1109/MPULS.2025.3640837","DOIUrl":"10.1109/MPULS.2025.3640837","url":null,"abstract":"<p><p>Substance use disorders (SUDs) remain a major public health challenge, exacerbated by limited access to care, low treatment engagement, and the disruption of services during the COVID-19 pandemic. Mobile phone applications (MPAs) offer a scalable mechanism for delivering behavioral health interventions; however, existing apps suffer from low engagement, limited methodological rigor, and inflexibility for research and clinical adaptation. This article presents Senyo, a proof-of-concept virtual treatment and research platform designed to support individuals with SUD while enabling systematic evaluation of mobile therapeutic strategies. The platform integrates an extensible mobile application with secure web-based portals for providers and researchers, enabling the delivery of asynchronous cognitive behavioral therapy (CBT) content, activity-based goals, and a token-economy-based contingency management (CM) reward system. Social reinforcement is incorporated through clinician messaging and tele-support, enhancing engagement and adherence. The researcher interface allows for real-time modification of modules, surveys, goals, and incentives without additional app development, facilitating blinded, randomized, and comparative studies within a single platform. The system is designed to be HIPAA compliant and aligned with emerging regulatory frameworks for software as a medical device. This work demonstrates the feasibility of a flexible, research-ready digital therapeutic infrastructure and outlines its potential to improve engagement, support evidence-based care, and advance rigorous evaluation of mobile interventions for SUD and related behavioral health conditions.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"53-63"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640838
Mary Bates
{"title":"Liquid and Synthetic Biopsies Are Poised to Rewrite Cancer Care.","authors":"Mary Bates","doi":"10.1109/MPULS.2025.3640838","DOIUrl":"10.1109/MPULS.2025.3640838","url":null,"abstract":"<p><p>Liquid biopsy is an innovative and promising alternative to traditional tissue biopsy for detecting and monitoring cancer. It involves analyzing cancer-related biomarkers, such as genetic material shed from tumors, in the blood or other body fluids. Synthetic biopsy is a related approach in which cancer cells are forced to produce biomarkers that reveal their presence. Liquid biopsy tests have been used for years to identify actionable genetic mutations that respond to certain targeted cancer therapies. Researchers are now working to integrate liquid and synthetic biopsies into other facets of cancer care, including screening and early detection, tracking disease progression, monitoring therapeutic response, and assessing minimal residual disease (MRD).</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"22-25"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640849
Muhammad Hamid Zaman
{"title":"Engineering Better Cancer Care in Low and Middle-Income Countries.","authors":"Muhammad Hamid Zaman","doi":"10.1109/MPULS.2025.3640849","DOIUrl":"10.1109/MPULS.2025.3640849","url":null,"abstract":"<p><p>Cancer deaths are rising in underserved regions, requiring context-specific research, equitable care, and accessible engineering solutions.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"50-52"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640842
Kristina Grifantini
{"title":"Lighting the Way to Treat Advanced Stomach Cancer.","authors":"Kristina Grifantini","doi":"10.1109/MPULS.2025.3640842","DOIUrl":"10.1109/MPULS.2025.3640842","url":null,"abstract":"<p><p>Advanced stomach cancer is incredibly difficult to treat, as tumor cells can hide throughout the abdomen, evading surgery and chemotherapy. Current treatments often cause severe side effects and are not fully effective. Researchers at the University of Texas are developing a new therapy that combines engineered proteins with near-infrared light to precisely target cancer cells, offering a promising, less toxic approach for stomach cancer.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"26-29"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640869
Chad Andresen
{"title":"Industry Corner Live With AngioDynamics CEO Jim Clemmer.","authors":"Chad Andresen","doi":"10.1109/MPULS.2025.3640869","DOIUrl":"10.1109/MPULS.2025.3640869","url":null,"abstract":"<p><p>Jim Clemmer, CEO of AngioDynamics, shares how he transformed the company into a science-driven innovator focused on cancer and cardiovascular disease through bold portfolio changes, deep physician engagement, and a strong market access strategy. His insights highlight the importance of agility, data-driven credibility, and aligning reimbursement early to bring groundbreaking MedTech technologies to market.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"71-74"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640857
Leslie Mertz
{"title":"Results in a Week to a Month.","authors":"Leslie Mertz","doi":"10.1109/MPULS.2025.3640857","DOIUrl":"10.1109/MPULS.2025.3640857","url":null,"abstract":"<p><p>Patient-grown microtumors on a chip let researchers test therapies in days and may even reveal which cancers are poised to spread.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"8-14"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640870
Amar Banerjee, Arnab Roy
{"title":"Detecting Role Impersonation in AI-Generated Clinical Oncology Text Using Knowledge Graphs.","authors":"Amar Banerjee, Arnab Roy","doi":"10.1109/MPULS.2025.3640870","DOIUrl":"10.1109/MPULS.2025.3640870","url":null,"abstract":"<p><p>Large language models (LLMs) are increasingly used in oncology for drafting radiology reports, pathology summaries, tumor-board notes, and clinical trial documentation. While their fluency and contextual adaptability enable workflow acceleration, such linguistic proficiency can conceal a critical risk: impersonation of oncologists or cancer researchers by mimicking professional tone without adhering to oncologic reasoning or procedural logic. This work presents a framework for detecting domain-level role impersonation in AI-generated oncology communication. Central to our method is the role impersonation index (RII), a composite metric that quantifies semantic fidelity and procedural coherence (PC) by aligning generated content with expert knowledge encoded in structured ontologies such as SNOMED CT, UMLS, and cancer-specific resources, including NCIt and OncoTree. Evaluated on 4,800 clinical oncology notes, balanced between human and AI authorship, our framework identifies inconsistencies in tumor terminology, diagnostic staging, biomarker logic, and therapeutic sequencing without relying on superficial linguistic cues, achieving an $F1$ -score of 94% and an AUROC of 0.96. By embedding cancer-domain semantics and established clinical workflows into the detection process, the proposed approach provides a principled safeguard for the trustworthy integration of generative AI in oncology practice. To our knowledge, this is the first framework that integrates knowledge-graph alignment with procedural logic scoring to detect role impersonation in cancer-related clinical documentation.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"75-86"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640845
Jim Banks
{"title":"Innovations in Cancer: Laser Light, AI, and Micromaterials.","authors":"Jim Banks","doi":"10.1109/MPULS.2025.3640845","DOIUrl":"10.1109/MPULS.2025.3640845","url":null,"abstract":"<p><p>Quality of life should be the top priority for patients with late-stage cancer, but standard chemotherapy treatments often bring great physical and emotional hardship in their final months. A new platform for injectable microparticles that combine thermal ablation and targeted chemotherapy at the tumor site may help is helping to change that, as well as opening up a new approach to treat the realm of therapeutic potential for cancer treatment at earlier stages. Jim Banks looks at the pioneering work of esteemed bioengineer Dr. Ana Jaklenec, principal investigator at the David H. Koch Institute for Integrative Cancer Research at MIT.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"5-7"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640852
Nathan Allen-Zimmerer
{"title":"Edge AI Is Reimagining What Home Cancer Care Can Be.","authors":"Nathan Allen-Zimmerer","doi":"10.1109/MPULS.2025.3640852","DOIUrl":"10.1109/MPULS.2025.3640852","url":null,"abstract":"<p><p>Home-based cancer care is expanding through telemedicine, yet patients often face long intervals between clinical visits with limited symptom surveillance. Edge artificial intelligence (Edge-AI) enables continuous physiologic monitoring using on-device analysis of wearable and sensor data, reducing reliance on cloud transmission and preserving privacy. Early clinical studies report reduced emergency department utilization, though survival outcomes remain unproven. Key challenges include clinical integration, alert workflow design, data governance, and equity in access. When responsibly implemented, Edge-AI may enhance timely intervention, protect patient autonomy, and support scalable home oncology care.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"35-38"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IEEE PulsePub Date : 2025-11-01DOI: 10.1109/MPULS.2025.3640860
Janet Rae-Dupree
{"title":"Bubbling Tumors Into Oblivion.","authors":"Janet Rae-Dupree","doi":"10.1109/MPULS.2025.3640860","DOIUrl":"10.1109/MPULS.2025.3640860","url":null,"abstract":"<p><p>An ultrasound treatment called histotripsy is opening new ways of thinking about cancer intervention. Using millimeter-sized points of hyper-focused ultrasound waves delivered noninvasively to liquefy tumors, histotripsy allows the body to reabsorb acellular debris after treatment. Currently approved by the FDA only for use in liver tumors, histotripsy is expected to expand broadly. While other treatments, including surgeries, may require stopping chemotherapy, histotripsy can be done simultaneously with systemic therapies. Because it is noninvasive, patients who otherwise may not be candidates for surgery can have their tumors treated. Histotripsy marks a turning point in cancer care and, down the road, potentially an array of noncancer issues. Unlike other technologies to remove unwanted body tissue, ablation with histotripsy involves no heat or irradiation and doesn't damage healthy tissue surrounding a tumor. Intriguingly, researchers are also discovering that its aftereffects may stimulate the immune system, prompting regression of untreated tumors throughout the body. They are currently working on how to combine its ultrasonic pulses with immunotherapy to help the body sic its own T-cells on recalcitrant tumors.</p>","PeriodicalId":49065,"journal":{"name":"IEEE Pulse","volume":"16 6","pages":"15-21"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}